For years, GLP-1 medications were viewed primarily as treatments for type 2 diabetes, with weight loss as a welcome side effect. Then came the SELECT trial—a landmark study that fundamentally changed how doctors think about these drugs. SELECT demonstrated that semaglutide (the active ingredient in Wegovy and Ozempic) reduces major cardiovascular events in people with obesity or overw... https://slimchecker.com/